Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: a Case Study for Pembrolizumab in the Netherlands.
Value in Health（2024）
Key words
Managed entry agreements,Value based Pricing,Cost-effectiveness,Pricing,Pharmaceutical pricing,Pembrolizumab
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined